The Impact of COVID-19 Outbreak on Trans-population's Health in Italy
Observational Evaluation of the Impact of COVID-19 Outbreak on Transgender Subject's Health and on the Organization of Trans-population Health Care Services
1 other identifier
observational
111
1 country
1
Brief Summary
During the COVID-19 outbreak, it was necessary to remodel the healthcare offer for all categories of subjects in order to minimize unnecessary movements of people while maintaining an adequate level of assistance. This is also true for transgender people, who are periodically requested to come into the clinic for hormonal therapy monitoring and continuation. In our center telemedicine programs dedicated to users have been activated for the remote management of hormone therapy. We use a web-based survey to assess the impact of COVID-19 outbreak on trans-population health and to assess the specific needs of this population in this particular moment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 20, 2020
CompletedFirst Submitted
Initial submission to the registry
June 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 20, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 20, 2020
CompletedFirst Posted
Study publicly available on registry
June 25, 2020
CompletedApril 29, 2021
April 1, 2021
1 month
June 1, 2020
April 28, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
Assessment of the specific health need of the transpopulation during the COVID-19 pandemic in Italy
Evaluation of the specific health care needs of this population
through study completion, an average of 6 months
Assessment of risk factors for COVID-19 infection in the traspopulation
Evaluation of socioeconomical and working condition of this population
through study completion, an average of 6 months
Secondary Outcomes (4)
Evaluation of the satisfaction of this population with telemedicine for hormonal treatment monitoring
through study completion, an average of 6 months
Evaluation of the psychological wellbeing of the trans-population during COVID-19 outbreak in Italy
through study completion, an average of 6 months
Evaluation of the psychological and physical wellbeing of the trans-population during COVID-19 outbreak in Italy
through study completion, an average of 6 months
Evaluation of the psychological and physical wellbeing of the trans-population during COVID-19 outbreak in Italy
through study completion, an average of 6 months
Interventions
Assess specific health care needs for the transpopulation during the COVID-19 outbreack using a newly created questionnaire and some validated questionnaries (Impact of Event Scale-Revised, BECK Depression Inventory and the Self-rated Health SF-12)
Eligibility Criteria
transgender population
You may qualify if:
- transgender subjects
- age \> 18 years
You may not qualify if:
- \- none
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
1Gynecology and Physiopathology of Human Reproduction, S. Orsola-Malpighi Hospital, Department of Medical and Surgical Sciences (DIMEC), University of Bologna
Bologna, 40138, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 1, 2020
First Posted
June 25, 2020
Study Start
May 20, 2020
Primary Completion
June 20, 2020
Study Completion
June 20, 2020
Last Updated
April 29, 2021
Record last verified: 2021-04
Data Sharing
- IPD Sharing
- Will not share